AlzeCure Pharma Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
ALZCUR
- Share Price
-
$0.64
- (As of Friday Closing)
AlzeCure Pharma General Information
Description
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
Contact Information
Website
www.alzecurepharma.seCorporate Office
- Hälsovägen 7
- 141 57 Huddinge
- Sweden
Corporate Office
- Hälsovägen 7
- 141 57 Huddinge
- Sweden
AlzeCure Pharma Stock Performance
As of 13-Nov-2026, AlzeCure Pharma’s stock price is $0.64. Its current market cap is $73.3M with 115M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.64 | $0.65 | $0.12 - $0.90 | $73.3M | 115M | 310K | $0.03 |
AlzeCure Pharma Financials Summary
As of 30-Jun-2026, AlzeCure Pharma has a trailing 12-month revenue of $10.4M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 49,130 | 18,885 | 5,665 | 15,572 |
| Revenue | 10,393 | 0 | 0 | 0 |
| EBITDA | 3,380 | (4,745) | (3,265) | (3,555) |
| Net Income | 3,280 | (4,850) | (3,342) | (3,497) |
| Total Assets | 12,593 | 6,416 | 3,558 | 3,785 |
| Total Debt | 207 | 278 | 329 | 456 |
AlzeCure Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AlzeCure Pharma Patents
AlzeCure Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026162570-A1 | Trka receptor modulators | Pending | 29-Jan-2025 | ||
| WO-2026162585-A1 | Trka receptor modulators | Pending | 29-Jan-2025 | ||
| WO-2026146201-A1 | New compounds and uses | Pending | 03-Jan-2025 | ||
| AU-2024444741-A1 | Triazinone derivatives for use in the treatment of inflammation | Pending | 09-May-2024 | ||
| WO-2025232990-A1 | Triazinone derivatives for use in the treatment of inflammation | Pending | 09-May-2024 | A61K31/53 |
AlzeCure Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AlzeCure Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
AlzeCure Pharma FAQs
-
When was AlzeCure Pharma founded?
AlzeCure Pharma was founded in 2012.
-
Where is AlzeCure Pharma headquartered?
AlzeCure Pharma is headquartered in Huddinge, Sweden.
-
What is the size of AlzeCure Pharma?
AlzeCure Pharma has 10 total employees.
-
What industry is AlzeCure Pharma in?
AlzeCure Pharma’s primary industry is Drug Discovery.
-
Is AlzeCure Pharma a private or public company?
AlzeCure Pharma is a Public company.
-
What is AlzeCure Pharma’s stock symbol?
The ticker symbol for AlzeCure Pharma is ALZCUR.
-
What is the current stock price of AlzeCure Pharma?
As of 13-Nov-2026 the stock price of AlzeCure Pharma is $0.64.
-
What is the current market cap of AlzeCure Pharma?
The current market capitalization of AlzeCure Pharma is $73.3M.
-
What is AlzeCure Pharma’s current revenue?
The trailing twelve month revenue for AlzeCure Pharma is $10.4M.
-
What is AlzeCure Pharma’s annual earnings per share (EPS)?
AlzeCure Pharma’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
